Form 4: Spyre Therapeutics CFO Trades Shares Under 10b5-1 Plan

Spyre Therapeutics, Inc. (SYRE) Chief Financial Officer, Scott L. Burrows, executed a series of stock transactions on April 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Scott L. Burrows, Chief Financial Officer of Spyre Therapeutics, Inc. (SYRE), engaged in stock transactions on April 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on November 10, 2025.
• Burrows acquired 7,500 shares of common stock at a price of $14.50 per share.
• He also disposed of a total of 7,500 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices of $49.21 and $49.98 per share.
• Following these transactions, Burrows beneficially owns 97,994 shares of common stock.
• This ownership includes 67,476 restricted stock units (RSUs) that vest in installments on September 1, 2026, and September 1, 2027.
• Burrows also holds a stock option to purchase 394,857 shares of common stock, with a portion vested and the remainder vesting over the next three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it details insider transactions, the use of a Rule 10b5-1 plan suggests these actions were pre-planned and do not necessarily reflect a change in the executive's outlook on the company's future performance.

Positives

• Acquisition of 7,500 shares at a lower price point ($14.50) suggests potential for future appreciation or a strategic purchase.
• The use of a Rule 10b5-1 plan indicates a pre-determined and structured approach to trading, mitigating concerns about insider trading.
• Continued vesting of RSUs and stock options tied to employment suggests ongoing commitment and potential future value realization for the CFO.

Negatives

• Disposal of 7,500 shares at significantly higher prices ($49.21 and $49.98) could indicate profit-taking by management.
• The substantial number of shares sold, even under a plan, might be interpreted by some investors as a lack of full confidence in near-term price appreciation.

Risks

• The Rule 10b5-1 plan itself is subject to market conditions and the company's performance, which could impact the execution and outcomes of future trades.
• Vesting of RSUs and stock options is contingent on continued employment, posing a risk if the reporting person's employment status changes.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the continued vesting of RSUs and stock options suggests a positive outlook for the reporting person's continued involvement and potential future equity value.

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common practice in the biotechnology and pharmaceutical sectors to manage personal stock portfolios while adhering to insider trading regulations. The specific prices and volumes traded in this Form 4 filing provide a snapshot of executive sentiment and potential liquidity management within Spyre Therapeutics.

Stakeholder Impact

• Shareholders: The transactions may influence market perception of insider confidence, though the Rule 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: Continued vesting of RSUs and options for the CFO reinforces the link between executive compensation and company performance.
• Management: Demonstrates adherence to regulatory requirements for reporting insider transactions.

Next Steps

• Continued vesting of RSUs on September 1, 2026, and September 1, 2027.
• Continued monthly vesting of stock options over the next three years.
• Potential future transactions under the Rule 10b5-1 plan, if applicable.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Options, Restricted Stock Units, Beneficial Ownership, Spyre Therapeutics, SYRE, Scott L. Burrows, CFO, Stock Transactions, Securities Exchange Act